Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Drops By 14.2%

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 354,100 shares, a drop of 14.2% from the December 31st total of 412,600 shares. Based on an average daily volume of 301,300 shares, the days-to-cover ratio is presently 1.2 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC raised its holdings in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 975,952 shares of the company’s stock after purchasing an additional 121,492 shares during the period. Renaissance Technologies LLC owned 1.81% of Spero Therapeutics worth $1,269,000 as of its most recent filing with the Securities and Exchange Commission. 25.60% of the stock is currently owned by institutional investors.

Spero Therapeutics Trading Down 1.5 %

Shares of Spero Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $0.86. 67,114 shares of the stock were exchanged, compared to its average volume of 194,923. The company has a market cap of $46.70 million, a price-to-earnings ratio of 12.24 and a beta of 0.63. Spero Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $1.89. The firm has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.20.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target on the stock. in a research report on Friday, December 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Spero Therapeutics in a research report on Thursday.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.